Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
The post Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again appeared first on Business News.
